多发性骨髓瘤血清β_2-MG及LDH检测的临床意义  

The clinical significance of β2-MG and LDH measuring in patients with MM

作　　者：葛祥花[1] 隋金财[1] 刘景玲[1] 孙桂珍[1] 

机构地区：[1]山东省临沂市人民医院血液科,276000

出　　处：《白血病．淋巴瘤》2006年第2期124-125,共2页Journal of Leukemia & Lymphoma

摘　　要：目的探讨多发性骨髓瘤(MM)患者血清β2-微球蛋白(β2-MG)和乳酸脱氢酶(LDH)检测的临床意义。方法分别采用速率法和放免法检测55例MM患者β2-MG和LDH值。结果正常组与MM组,Ⅲ期与Ⅱ期,Ⅱ期与Ⅰ期,以及化疗前与化疗后(CR组或PR组)患者β2-MG及LDH相比,后组均明显高于前组,差异有统计学意义(P<0.05),而无效组化疗前后差异无统计学意义(P>0.05)。结论血清β2-MG和LDH水平可作为患者分期、预后及疗效判断的辅助指标。Objective To evaluate the clinical significance of the serum β2-microglobulin （β2-MG） and lactic dehydrogenase （LDH） measuring in MM patients. Methods The β2-MG and LDH are collected from 55 MM patients and measured by rate method and radioimmunoassay respectively. Results All samples are classified into phase Ⅰ or phase Ⅱ or phase Ⅲ, group A or group B, chemotherapy complete remission or chemotherapy partial remission（CR or PR） accordingly for comparison prose. It are found that value of β2-MG and LDH for all patients in the later category of the comparison pair mentioned. Above are obviously higher than that in their comparison counterpart and the difference is of significance （P 〈0.05）, while the difference for chemotherapy ineffective group before and after chemotherapy seems of less significance （P 〈 0.05）. Conclusion The level of β2-MG and LDH can be taken as an auxiliary clinical index to classify the phase of prognosis and effectiveness of treatment in MM patients.

关 键 词：多发性骨髓瘤 Β2-MG LDH 

分 类 号：R733.3[医药卫生—肿瘤]